Intentar ORO - Gratis
FROM GENES TO CARE: ADVANCING CLINICAL UNDERSTANDING OF HYPOPHOSPHATASIA
Healthcare Radius
|December 2025
From genes to care, the story of hypophosphatasia reminds us that progress in medicine isn't only about scientific discovery, it's about turning knowledge into healing.
Bringing a Rare Condition into the Spotlight
Every so often, a rare disorder teaches us something profound about human biology and the impact of how personalised medicine can change lives. Hypophosphatasia, often abbreviated as HPP is one such example. Though few people have heard of it, its story bridges genetics, biochemistry, and compassionate care.
For decades, this condition puzzled doctors. Babies were born with bones so soft that they couldn't support breathing. Adults suffered repeated stress fractures that never healed properly. Some patients lost teeth early in life for no obvious reason. All shared one hidden trait unusually low levels of an enzyme called alkaline phosphatase.
We now know that hypophosphatasia is an uncommon genetic disorder that can range from minor oral issues to potentially fatal skeletal disease, making it more than just a medical curiosity. Additionally, there are now therapeutic possibilities that were previously unthinkable because of current science.
The Role of a Single Gene
The underlying cause of hypophosphatasia is a defect in a single gene, ALPL. It carries the instructions for an enzyme called tissue-nonspecific alkaline phosphatase (TNSALP). This enzyme plays a quiet but essential role in helping our bones and teeth form properly. It acts like a molecular “cleanup crew,” clearing away substances that would otherwise interfere with bone mineralisation.
When mutations occur in the ALPL gene, the body produces too little of this enzyme, or it doesn't work correctly. One of the substances that builds up as a result is inorganic pyrophosphate, a natural inhibitor of bone formation. The higher its concentration, the harder it becomes for calcium and phosphate to bond and form strong bones and teeth.Esta historia es de la edición December 2025 de Healthcare Radius.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE Healthcare Radius
Healthcare Radius
VENUS REMEDIES GETS DRUG APPROVALS IN VIETNAM
Venus Remedies, a fixed-dosage injectable manufacturer, has secured new marketing authorisations for Methotrexate, Cefuroxime, and Irinotecan in Vietnam.
1 mins
December 2025
Healthcare Radius
A HEALTHIER INDIA IN THE MAKING: LEADERS DECODE THE ROAD FROM 2025 TO 2026
The collective goal is clear and unanimous: to transition from a system that primarily treats sickness to one that actively promotes lifelong health and well-being.
12 mins
December 2025
Healthcare Radius
FROM GENES TO CARE: ADVANCING CLINICAL UNDERSTANDING OF HYPOPHOSPHATASIA
From genes to care, the story of hypophosphatasia reminds us that progress in medicine isn't only about scientific discovery, it's about turning knowledge into healing.
6 mins
December 2025
Healthcare Radius
ALEMBIC PHARMA GETS USFDA NOD FOR DILTIAZEM TABLETS IN THE US
Alembic Pharmaceuticals (Alembic) Aamour announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg.
1 min
December 2025
Healthcare Radius
ZYDUS GETS USFDA APPROVAL FOR PROSTATE CANCER INJECTABLE
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial (USRLD: Lupron Injection®, 1 mg/0.2 mL).
1 min
December 2025
Healthcare Radius
SUPERHEALTH LAUNCHES HONEST SECOND OPINION FOR PATIENTS
Superhealth, a zero-wait, commission Superhealth, zerohospital network, announced the launch of \"Honest Second Opinion,\" a service that helps patients make informed decisions about their treatment plans and surgical recommendations.
1 min
December 2025
Healthcare Radius
KOTAK ALTS INVESTS RS 400MN IN MEDIVERSAL
Kotak Alternate Asset Managers (Kotak Alts), through its Kotak Life Science Fund I, which invests in early to growth-stage life sciences and healthcare businesses, has made an investment of Rs 400 million in Mediversal Healthcare.
1 min
December 2025
Healthcare Radius
INVIGA HEALTHCARE FUND ACQUIRES 21% STAKE IN FORUS HEALTH
Inviga Healthcare Fund (IHF), the private equity platform founded by Dr B. S. Ajaikumar of HCG, has acquired a 21 per cent stake in Forus Health, an ophthalmic diagnostics company whose devices have screened over 22 million patients across 75+ countries.
1 min
December 2025
Healthcare Radius
OPTIMISING MATERNITY OPS: REDUCING C-SECTION BURDEN THROUGH EVIDENCE-BASED PROTOCOLS
By building systems that support safety, documentation, and respectful care, institutions can improve outcomes, lower litigation risks, and strengthen quality scores, achieving what healthcare should truly represent: Care Through Trust.”
7 mins
December 2025
Healthcare Radius
MENTAL HEALTH CARE GOES DIGITAL WITH NEW THERAPY PLATFORM
Following the global observance and continuing the commitment to mental well-being, renowned clinical psychologist Kanika Jindal announced the launch of Harmony Therapy World, a holistic digital platform designed to bring emotional healing and psychological support to people everywhere, privately, compassionately, and without barriers.
1 min
December 2025
Listen
Translate
Change font size
